Nootropics Index - Save on smarter supplements
Nootropics>Botanical & herbal supplements>Saw Palmetto
Botanical & herbal supplements

Saw Palmetto

Saw palmetto (Serenoa repens) berry extract

Saw palmetto (Serenoa repens) has no demonstrated human cognitive benefit. For urinary symptoms associated with benign prostate enlargement, a 2023 Cochrane review and two randomized trials found little to no benefit for saw palmetto used alone.

Whole HerbStandardized ExtractFood DerivedClinical ResearchLimited Human EvidenceMixed EvidenceForm Dependent Evidence
Updated August 2026/4 min read/6 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What saw palmetto is

2

Saw palmetto is the common name for Serenoa repens, a botanical whose berries are used in dietary-supplement products.

Nootropic evidence5
The cited systematic review evaluates urinary symptoms associated with benign prostate enlargement, not memory, focus, or mental energy. It does not support a nootropic claim.
02

Names, aliases and forms

Common NameSaw palmetto
Latin NameSerenoa repens
03

Potential effects and evidence map

Human evidence does not support saw palmetto as a nootropic. The 2023 Cochrane review concluded that Serenoa repens alone provides little to no benefit for lower urinary tract symptoms associated with benign prostate enlargement. Standard-dose and escalating-dose trials also found no benefit over placebo. Product formulation remains relevant to comparison, but it does not establish cognitive efficacy.

Effect domainMagnitudeGrade
Memory / learning5
UnknownConfidence: High

The cited systematic review evaluates urinary symptoms, not memory or learning; it does not support a cognitive claim.

Note Urinary-symptom research does not establish a cognitive effect.

0/5
E
04

Typical dosages and timing

Study range4320 to 960 mg/day

A randomized trial escalated a saw palmetto extract from 320 to 960 mg/day and found no improvement in urinary symptoms versus placebo. This is study context, not a personal dose recommendation.

05

Timing & effect horizon

Effect horizonUnknown
Unknown
Study window4Cumulative
72 weeks
06

Safety, side effects and risk profile

Evidence uncertainty5
Confidence: High

A Cochrane review found little to no benefit for saw palmetto used alone for lower urinary tract symptoms associated with benign prostate enlargement.

Note Form and combination-product differences do not establish nootropic benefit.

2/5
B
Pregnancy / lactation caution2
Confidence: High

NCCIH says saw palmetto may be unsafe during pregnancy or while breastfeeding.

Note This is a pregnancy and lactation evidence limitation, not a claim about every product.

4/5
C
GI discomfort2
Confidence: High

NCCIH describes digestive symptoms as mild and infrequent adverse effects in research studies.

Note The source does not provide a reliable individual event-rate forecast.

1/5
C
Headache / dizziness2
Confidence: High

NCCIH describes dizziness and headache as mild and infrequent adverse effects in research studies.

Note This is tolerability information, not a claim of impairment or a universal interaction warning.

1/5
C
Reported effects2mild and infrequent

NCCIH reports that saw palmetto was well tolerated in research studies for up to 3 years. Reported adverse effects include digestive symptoms, dizziness, and headache.

07

Interactions and cautions

General caution2

NCCIH advises people taking any medicines to discuss herbal products with a health professional because harmful herb-medicine interactions can occur. Its saw palmetto page does not provide a universal product-specific interaction list.

08

Legal and regulatory status

Status2

As of 2026, dietary supplements in the United States are not approved by FDA before sale. Manufacturers and distributors are responsible for evaluating safety and labeling before marketing, and FDA can act when public-health concerns arise. This is U.S. regulatory context, not a global approval determination.

09

How it compares

Formulation context2

NCCIH reports that analyses of hexane-extracted and other saw palmetto products found no difference in effects on BPH symptoms. Compare the exact extract and label; form differences do not establish cognitive benefit.

10

Practical buying and quality notes

  • The dated catalog snapshot contains 13 powder and nine capsule rows. Repeat-crawl rows and form-specific quantities or prices make a universal best-price, per-dose, or extract-equivalence ranking unreliable; confirm the exact label before comparing.6
11

FAQ

Does a higher saw palmetto dose change the evidence?

4

The escalating-dose trial did not improve urinary symptoms versus placebo. Higher study doses did not establish a nootropic effect or a personal dose recommendation.

Is saw palmetto supported for memory or focus?

5

The clinical sources cited here assess urinary symptoms, not memory or focus. Urinary-symptom research should not be presented as cognitive evidence.

How long was saw palmetto studied?

4

The escalating-dose trial followed urinary symptoms for 72 weeks and found no benefit over placebo. That study duration does not establish an onset, effect duration, or cycling protocol.

12

References

  1. NCBI Taxonomy Browser. Serenoa repens, taxonomy ID 4722.
  2. National Center for Complementary and Integrative Health. Saw Palmetto: Usefulness and Safety.
  3. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins AL. Saw palmetto for benign prostatic hyperplasia. New England Journal of Medicine. 2006.
  4. Barry MJ, Meleth S, Lee JY, et al.; CAMUS Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011.
  5. Franco JVA, Trivisonno L, Sgarbossa NJ, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Database Syst Rev. 2023.
  6. NootropicsIndex Saw Palmetto product catalog snapshot, 1 August 2026.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.